Bangladesh expansion
Theranostics Bangladesh Feasibility Brief
Executive summary
The verdict: GO — conditional on five gating items. The question is not whether Bangladesh needs domestic theranostics capacity — that demand is already proven by the billions its patients spend escaping the country for cancer care each year. The question is who moves first.
The clinical model this brief is built on — radioligand therapy pairing a diagnostic and therapeutic isotope on the same targeting molecule — is an approved, growing global standard, not a speculative bet. What only a domestic cyclotron can add is access to alpha-emitting isotopes like Astatine-211, whose 7.2-hour half-life makes it physically impossible to import. Owning production converts Bangladesh’s current isotope-supply dependency into a national asset.
What’s inside
- The opportunity — why Bangladesh, why now: the demand engine, the disease burden, and a country already on the runway.
- The solution — a national, hub-and-spoke theranostics and isotope-production model.
- The clinical evidence — drawn from a 13-paper research corpus on alpha therapy and radioembolization outcomes.
- What it takes to build — the cyclotron, the facility, the people, and the regulatory path.
- The economics — the revenue and cost logic, and the market tailwind.
- Risks & mitigations, and a staged roadmap for establishing the capability.
Get the full brief
The complete brief — including the detailed economics, staged roadmap, and full evidence appendix — is available on request to investors, hospital leadership, medical physicists and clinicians working on Bangladesh’s cancer-care capacity.